Claims for Patent: 11,617,747

Summary for Patent: 11,617,747

Title:	Bupropion as a modulator of drug activity
Abstract:	Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US17/471,983
Patent Claims:	1. A method of increasing dextromethorphan plasma levels, comprising co-administering bupropion and dextromethorphan once a day or twice a day for at least 8 consecutive days to a human being who is a non-poor metabolizer of dextromethorphan; wherein about 50 mg to about 220 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 40 mg to about 60 mg of dextromethorphan in a salt form, or a molar equivalent amount of the free base form of dextromethorphan, once a day or twice a day; and wherein co-administering the bupropion and the dextromethorphan results in a Cmax of dextromethorphan on the eighth day that is about 15 times to about 1,150 times the Cmax of dextromethorphan that results after the first dose of the bupropion and the dextromethorphan are co-administered. 2. The method of claim 1, wherein co-administering the bupropion and the dextromethorphan results in a Cmax of dextromethorphan on the eighth day that is about 15 times to about 50 times the Cmax of dextromethorphan that results after the first dose of the bupropion and the dextromethorphan are co-administered. 3. The method of claim 1, wherein co-administering the bupropion and the dextromethorphan results in a Cmax of dextromethorphan on the eighth day that is about 20 times the Cmax of dextromethorphan that results after the first dose of the bupropion and the dextromethorphan are co-administered. 4. The method of claim 2, wherein about 70 mg to about 150 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 40 mg to about 60 mg of dextromethorphan in the salt form, or a molar equivalent amount of the free base form of dextromethorphan, once a day or twice a day to the human being. 5. The method of claim 4, wherein the AUC0-12 of dextromethorphan on the eighth day is about 750 ng·hr/mL. 6. The method of claim 4, wherein the AUC0-12 of dextromethorphan on the eighth day is about 700 ng·hr/mL to about 1686 ng·hr/mL. 7. The method of claim 6, wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of the free base form or another salt form of bupropion, is co-administered with about 44 mg to about 46 mg of dextromethorphan in the salt form, or a molar equivalent amount of the free base form of dextromethorphan, once a day or twice a day to the human being. 8. The method of claim 6, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 9. The method of claim 6, wherein the Cmax of dextromethorphan on the eighth day is about 70 ng/mL to about 158 ng/mL. 10. The method of claim 9, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 11. The method of claim 9, wherein the Cmin of dextromethorphan on the eighth day is about 40 ng/mL to about 119 ng/mL. 12. The method of claim 11, wherein the bupropion and the dextromethorphan are co-administered to the human being for the treatment of depression. 13. The method of claim 11, wherein the bupropion and the dextromethorphan are co-administered once a day or twice a day to the human being for at least 14 consecutive days. 14. The method of claim 11, wherein the bupropion and the dextromethorphan are co-administered once a day or twice a day to the human being for at least 30 consecutive days. 15. The method of claim 11, wherein the human being is converted to poor metabolizer of dextromethorphan on the eighth day after co-administering the bupropion and the dextromethorphan.